During the second wave of the pandemic in India the number of COVID-19 cases spiked exponentially. It was quickly realised that universal vaccination is the only endgame for the crisis. While vaccines were being manufactured at accelerated speeds, administering them to the eligible population across the length and breadth of the country was an insurmountable challenge. Most of the COVID-19 vaccines administered in India require some form of cold storage. Even a single transport leg or storage port that isn’t temperature-controlled puts the potency of the vaccine at risk. Given India’s inadequate infrastructure to efficiently meet the vaccines’ temperature and storage requirements, there was an urgent need to strengthen India’s cold chain management to achieve the national goal of universal vaccine coverage.

Celsure® containers

PLUSS provides Celsure® containers that maintain precise temperatures between 2°C – 8°C, 15°C – 25°C and -20°C, for up to 5 days. These containers are made from ‘phase change materials’ using the concept of thermal energy storage, to maintain the inside temperature without electricity. As the desired temperatures can be maintained for up to 120 hours, these containers bring operational and cost efficiency in transport of temperature-sensitive products. They are used by pharma, diagnostics and biotech companies to pack and transport temperature sensitive drugs, vaccines, test kits, clinical trial samples, and other products that require a constant temperature to maintain their efficacy. PLUSS was the proud recipient of Government of India’s Technology Day Award, 2021 for its Celsure® range of pharmaceutical cold-chain packaging solutions.